Project Grant R01AA031664
Award Date 9/20/25
Completion Date 8/31/29
Dollars Obligated $3.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- This federal Project Grant award of $672,377 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) aims to assess the efficacy of cannabidiol (CBD) as an adjunct treatment for alcohol withdrawal and craving in patients with alcohol use disorder (AUD). The 5-year study will recruit participants with moderate-to-severe AUD and randomize them to receive placebo, 10 mg/kg CBD, or 20 mg/kg CBD while undergoing medical detoxification....
- This Project Grant award, totaling $268,470.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The project will study the impacts of recent state-level laws legalizing medical cannabidiol (CBD) on substance use, including CBD use, opioid use, and alcohol use, as well as associated overdose rates. The research team, led by the RAND Corporation, will also collect and publish data on CBD dispensary locations and...
- This federal Project Grant award of $123,045.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) grant program. The award supports research to investigate interactions between the alcohol and cannabinoid systems in the context of pain and alcohol use disorder (AUD). The project aims to examine the potential analgesic effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, on pain...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $686,692 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina. The grant will fund an 8-week clinical trial to assess the prospective changes in patient-reported and objective functioning following reduction of cannabis use among adults with cannabis use disorder. The trial will evaluate the benefits of cannabis harm...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
- This $407,812 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) will fund a study by the University of Oregon examining the dynamic associations between impulsivity, craving, and co-use of alcohol, cannabis, and nicotine among young adults. The study aims to collect intensive longitudinal data from 250 young adults to investigate how impulsiveness and craving vary between and within different substance use episodes, with a...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study on the prevalence and characteristics of cannabidiol (CBD) use during pregnancy. The study aims to: 1) Estimate the prevalence of CBD use overall and by trimester in a clinical sample of 800 pregnant women receiving prenatal care at the University of Colorado; 2) Characterize women who use CBD and/or cannabis during pregnancy in terms...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $550,417 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Texas at Austin. The grant, effective September 1, 2025 through May 31, 2030, supports research to investigate how heavy alcohol exposure in aging individuals leads to impaired microglia function, neurodegeneration, and cognitive deficits. The study aims to determine whether dysregulated neuroimmune and microglia responses are...